Transcend Therapeutics is a biotechnology company that is revolutionizing the way people treat neuropsychiatric illnesses. Their mission is to discover, develop, and deliver the next generation of psychoactive compounds, with the goal of providing better access to treatments for those suffering from mental illnesses.

The team at Transcend Therapeutics is comprised of experienced professionals, including the first scientist to receive federal funding for clinical psychedelic research in 54 years and a drug development executive with pivotal contributions to 9 FDA approvals.

What makes Transcend Therapeutics stand out from other businesses in the same industry is their focus on compounds with clinical and nonclinical safety profiles in the public domain, as well as treatments with benefits over classic psychedelics. These benefits include the ability to administer while patients are on traditional antidepressants, a short treatment duration, minimal patient inebriation, and lack of undesirable subjective effects.

Transcend Therapeutics is driven by the goal of reducing the global economic burden of mental illness, which is estimated to reach $6 trillion by 2030. By providing better treatments and access to those suffering from mental illnesses, they aim to make a positive impact on the world.